Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 25Hodgkin Disease 20Lymphoma 9Skin Neoplasms 4Neoplasm Metastasis 4Sarcoma 3Leiomyosarcoma 3Neuroblastoma 2Neoplasms 2Uveal Melanoma 1Skin Diseases 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Recurrence 1Melanoma, Cutaneous Malignant 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Liposarcoma 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Dacarbazine × Clear all
NCT01227889 2017-10-04

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

GlaxoSmithKline

Phase 3 Completed
251 enrolled 21 charts
Dermatologic

Melanoma, Neoplasms

NCT00003647 2008-07-25

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

Vical

Phase 3 Completed
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡